KL-A167

KL-A167 is an investigational agent whose form is not stated in the registry developed by Sichuan Kelun-Biotech Biopharmaceutical. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: KL-A167 4-6 cycles for combined therapy.KL-A167 maintenance. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT05294172 (KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma), in nasopharyngeal carcinoma and non-small-cell lung cancer. The largest, NCT05294172, plans to enrol 295 participants (actual) with primary completion expected 2027-12. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.